The July 2026 Meeting: Approval Pathways Ahead The FDA has scheduled a July 2026 public meeting to explore formal approval pathways for these and similar peptides
Symptoms suggestive of dumping syndrome after provocation in patients after laparoscopic sleeve gastrectomy
This section is arguably the most practically important part of this entire guide, because GI side effects are the primary reason people discontinue either medication
The health benefits of significant weight loss typically outweigh the temporary inconvenience of managing this side effect
So EGF is a plausible cell-renewal signal with a real mechanism, not a guaranteed pigment shield, and a randomized controlled trial of microneedling combined with topical growth factors did report improvements in skin parameters with no adverse effects, which supports the pairing of needling and growth-factor delivery while stopping well short of overpromising
Additionally, you may be able to deduct for accessibility changes you made to your house, such as adding a wheelchair ramp
